Professor Dame Sarah Gilbert
Old Road Research Campus Building, Headington, Oxford, OX3 7DQ
Said Professorship of Vaccinology (DBE)
- Dame Commander of the Most Excellent Order of the British Empire (DBE), for services to Science and Public Health
Professor Gilbert joined the Nuffield Department of Medicine at Oxford University in 1994 and became part of the Jenner Institute (within NDM) when it was founded in 2005. Her chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses. She leads work on influenza vaccine development as well as vaccines for many different emerging pathogens, including Nipah virus, MERS, and Lassa virus.
Professor Gilbert’s work also focuses on the rapid transfer of vaccines into GMP manufacturing and first in human trials. This is achieved through collaboration with colleagues in the Clinical Biomanufacturing Facility and Centre for Clinical Vaccinology and Tropical Medicine, all situated on the Old Road Campus in Oxford.
In 2020 Professor Gilbert became the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus SARS-CoV-2. This vaccine, tested by the University of Oxford in clinical trials of over 23,000 people in the UK, Brazil and South Africa, is now in use in many countries around the world in the fight against the Covid-19 Pandemic.
‘I have worked in the development of vaccines against infectious pathogens for many years and in the last 2 years have been able to draw on all that I have learned in order to respond to the SARS-CoV-2 pandemic. I have been so fortunate to work with a very talented and dedicated team who made it possible to develop a vaccine in less time than anyone thought possible.’
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
Folegatti PM. et al, (2020), The Lancet Infectious Diseases, 20, 816 - 826
A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques
van Doremalen N. et al, (2020), Science Advances, 6
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.
van Doremalen N. et al, (2022), Nature communications, 13
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe A. et al, (2022), JCI Insight, 7
CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
Sharpe HR. et al, (2022), JCI Insight, 7
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.
van Doremalen N. et al, (2022), Res Sq
ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
Lambe T. et al, (2021), Communications Biology, 4
list of public engagement